Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Mechanical environment modulates biological properties of oligodendrocyte progenitor cells.
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
The interplay between the intestinal microbiota and the brain.
Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
New multiple sclerosis phenotypic classification.
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Natalizumab Use During the Third Trimester of Pregnancy.
Biogen Idec receives negative opinion from the CHMP on Fampyra
LKB1-regulated adaptive mechanisms are essential for neuronal survival following mitochondrial dysfunction.
Patient reported outcome measures in neurogenic bladder.
Acorda Therapeutics announces initiation of AMPYRA® proof-of-concept study in patients with post-stroke deficits
Uhthoff's phenomena in MS-clinical features and pathophysiology.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Oligodendrocyte death results in immune-mediated CNS demyelination.
A novel oral nutraceutical formula of omega-3 and omega-6 fatty acids with vitamins (PLP10) in relapsing remitting multiple sclerosis: a randomised, double-blind, placebo-controlled proof-of-concept clinical trial.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
Novel therapies for memory cells in autoimmune diseases.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
Santhera to discontinue sale of Catena® in Canada
New approaches in the management of multiple sclerosis.
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants

Pages